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Abstract  Recent reductions in healthcare funding in the United States has pressured clinical laboratories to 
provide the same quality of diagnostic testing with fewer resources. Testing cascades have been developed to assist 
in the diagnosis of various illnesses, which use fewer tests and subsequently reduce costs. However, the cost 
effectiveness of a celiac disease (CD) testing cascade compared to a panel is currently unknown. Therefore, the 
purpose of this study was to determine if a CD testing cascade was equivalent to a panel in identifying patients 
deemed likely for CD, and to compare their cost effectiveness in a sample of symptomatic patients from Northeast 
Tennessee. A retrospective analysis using a CD testing cascade was performed on 933 outpatient samples referred to 
our laboratory from 2012 to 2017 with a request for a celiac disease serology panel. The seroprevalence of CD for 
the panel and the cascade were the same in this population (1.82%, 95% binomial confidence interval: 1.06% to 
2.90%). The total cost of the CD cascade was 268% less than the cost of the panel resulting in a savings of $44,705, 
which translates to a savings of $47.92/patient. Based on these findings, we recommend utilization of the cascade to 
identify patients with likely CD. In the future, creative use of novel testing strategies can have significant 
contributions to healthcare reform and afford patients more cost-effective clinical diagnostic testing. 
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1. Introduction 
Celiac disease (CD) is an immune-mediated inflammatory 
reaction to dietary gluten which results in injury to the 
mucosa of the small intestine with a loss of absorptive surface 
area [1,2]. The seroprevalence of CD in the general population 
is between 0.8-1% [1,3,4] and is on the rise. Despite rising 
diagnosis rates [1,4,5], CD remains underdiagnosed in the 
United States [1]. Currently, the favored strategy for 
increasing detection of CD is an active-case finding approach 
involving serological testing of patients with symptoms 
(e.g. abdominal pain, diarrhea, chronic fatigue) or conditions 
(e.g. irritable bowel syndrome, Down syndrome, Turner 
syndrome) closely associated with CD. Among adult patients 
with chronic abdominal symptoms, tissue transglutaminase 
(TTG IgA) and endomysial antibodies (EMA IgA) have 
the highest accuracy for diagnosis of CD. In IgA deficient 
patients, TTG IgG, EMA IgG or deamidated gliadin 
peptides (DGP IgG) are measured to screen for possible 
CD. Despite advancements in serological testing for  
CD, small intestinal biopsy with histology remains the  
gold-standard for diagnosing CD. Considering the invasiveness 
and expense of intestinal biopsies, serological testing 
cascades have been developed to identify patients who are 
at a higher risk for CD. 
Recent healthcare reform has led to the progressive 
contraction of healthcare funding [6,7]. As a result, 
clinical laboratories have been pressured “to do more with 
less” to provide the same quality of diagnostic testing with 
fewer resources. Historically, laboratories have used 
testing cascades to assist in diagnosis of various illnesses, 
which use fewer tests and subsequently reduce costs. 
While use of cascades for various illnesses (e.g. bacterial 
infections [8], hypercholesterolaemia [9], sepsis [10]) 
have been shown to save money, physicians often order a 
testing panel consisting of multiple assays. Various testing 
cascades currently exist for CD from national clinical 
laboratories (Mayo medical laboratories, ARUP, LabCorp); 
however, their cost effectiveness compared to a CD panel 
is currently unknown. Therefore, the purpose of this study 
was to determine if a CD testing cascade was equivalent to 
a panel in identifying patients deemed likely for CD,  
and to compare their cost effectiveness in a sample of 
symptomatic patients from Northeast Tennessee. 
2. Materials and Methods 
2.1. Study Sample 
The patient population consisted of 933 consecutive 
outpatient samples (male=299, female=634, age=45.06 ± 
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19.84) referred to our laboratory from January 1st, 2012 to 
August 1st, 2017 with a request for a celiac serology panel 
to be performed. Samples were analyzed at East Tennessee 
State University (ETSU) Clinical Laboratories, Quillen 
College of Medicine. The ETSU Institutional Review 
Board (IRB) determined that the study did not meet the 
definition of human subjects’ research and therefore did 
not require IRB review and approval. 
2.2. Laboratory Analyses 
Immunoglobulin A testing was performed on an 
automated chemistry analyzer (Beckman Coulter AU 480, 
Bellport, NY) using the immunoturbidimetric IgA assay 
(Kamiya Biomedical Company, Tukwila, WA). The CD 
assays: TTG IgA, DGP IgA, TTG IgG, DGP IgG were 
performed on a Phadia 250 Immunoassay Analyzer 
(assays and analyzer purchased from Fisher Scientific, 
Hampton, NH). The EMA IgA test was performed at 
Laboratory Corporation of America (Burlington, NC).  
The CD panel included the following assays: IgA, TTG 
IgA, EMA IgA, DGP IgA, DGP IgG. In our subsequent 
retrospective analysis we applied the results from the 
panel to a cascade we developed based in principle on 
Mayo clinical laboratories CD cascade (Figure 1). For the 
CD cascade, samples with IgA≥7 mg/dL (n=933) were 
applied to TTG IgA and were further grouped based on 
the package insert reference ranges: TTG IgA>10U/mL, 
positive; 7-10 U/mL, equivocal; <4U/mL, negative. 
Patient samples with IgA <7 mg/dL were removed from 
the analyses due to the small sample size (n=8). 
2.3. Statistical Analyses 
Prevalence rates for positive serology are expressed  
as a percentage of the total number of patient samples with  
95% binomial confidence intervals (CIs) based on the 
criteria used by Katz et al., [4]. Namely, a positive TTG 
IgA or equivocal TTG IgA with either positive EMA IgA 
or DGP IgA were deemed likely for CD. Reimbursements 
for the various tests were obtained from the 2017 
Medicare Clinical Diagnostic Laboratory Fee Schedule for 
Tennessee. Grand total cost for the CD panel and cascade 
were compared to assess cost effectiveness. Analyses  
were conducted using Microsoft Excel 2013 (Microsoft 
Corporation, Redmond, WA, USA). 
 
Figure 1. CD Testing Cascade with results 
3. Results 
Overall the seroprevalence of CD in this population of 
patients from Northeast Tennessee was 1.82% (95% CI: 
1.06% to 2.90%) with 17 of 933 positive samples. The CD 
cascade successfully captured all patients deemed likely 
for CD. The EMA IgA results for 1 patient sample were 
positive with all other tests negative, thus this patient was 
considered unlikely for CD. The seroprevalence of CD in 
pediatric (<18yr, 2 of 99) and adult samples (>18yr, 15 of 
834) was similar. Therefore, the results from both of these 
groups were combined for further analyses. The total cost 
of the CD cascade was 268% less than the cost of the 
panel resulting in a savings of $44,705 (Table 1). 
Furthermore, the panel cost $76.42/patient, whereas the 
cascade cost $28.50/patient, resulting in a savings of 
$47.92/patient. 
Table 1. Cost analysis for CD panel vs. cascade 
 Panel Cascade 
Assay Number of tests *Cost/assay Total Cost Number of tests *Cost/assay Total Cost 
IgA 933 $12.76 $11,905 933 $12.76 $11,905 
IgA TTG 933 $15.71 $14,657 933 $15.71 $14,657 
IgA DGP 933 $15.71 $14,657 1 $15.71 $15.71 
IgG DGP 933 $15.71 $14,657 0 $15.71 $0.00 
IgA EMA 933 $16.53 $15,422 1 $16.53 $16.53 
Total Cost $71,300 $26,595 
*Cost/assay determined from 2017 Medicare Clinical Diagnostic Laboratory Fee Schedule for Tennessee. 
 
4. Discussion 
The purpose of this study was to determine if a CD 
testing cascade was equivalent to a panel in identifying 
patients deemed likely for CD, and to compare their cost 
effectiveness in a sample of symptomatic patients from 
Northeast Tennessee. Our results showed that the CD 
cascade captured all patients with a high probability of CD 
and did so at a much lower cost compared to the panel. 
The seroprevalence of CD in the present study (1.82%) 
was slightly greater than that reported for the general 
population (0.8% to 1.0%) [1,3,4]. This is likely because 
the present study only tested symptomatic patients.  
Also, it is important to note that IgA deficient samples  
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(<7 mg/dL) were not included in this analysis and may 
have influenced the observed seroprevalence rate. 
Recent reductions in healthcare funding has pressured 
clinical laboratories to provide the same quality of 
diagnostic testing with fewer resources. The findings from 
the current study support the use of a CD cascade that 
resulted in lower costs, but still captured all patients with a 
high probability of CD. In support of our findings, 
unpublished data from Mayo Clinical Laboratories also 
determined that a CD cascade resulted in a savings of 
$39,527 and a diagnosis rate of 87% compared to a 
hospital-ordered panel over a 12-month period [11]. 
Cascades used for other illnesses have also been effective 
at reducing costs while maintaining diagnosis rates. For 
example, a family screening strategy for hypercholesterolemia 
resulted in a cost savings of ~$13,638/case detected 
compared to a universal screening method in the United 
Kingdom [9]. To further illustrate the impact on 
healthcare spending, if the current CD cascade was used 
instead of the panel in 1,000 clinical laboratories across 
the United States it would result in a cost savings of nearly 
$40 million. Considering the rising CD diagnosis rates and 
hospital discharges for celiac disease [1,12], reducing 
healthcare spending through the use of cascades is 
paramount. Future research should address the utility and 
cost benefit of cascades compared to other panels used to 
screen for relatively common diseases. 
5. Conclusions 
The seroprevalence of CD for the panel and the cascade 
were the same (1.82%) in a sample of symptomatic 
patients from Northeast Tennessee over a 4.5-year period. 
However, the CD cascade resulted in a $47.92 savings/patient 
compared to the panel. Based on these findings, we 
recommend utilization of the cascade to identify patients 
with likely CD. In the future, creative use of novel testing 
strategies can have significant contributions to healthcare 
reform and afford patients more cost-effective clinical 
diagnostic testing. 
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